clinical trial · NCT05748197
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Acute Myeloid LeukemiaADCLEC.syn1 CAR T cellsConditioning chemotherapy
brief summary
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.
started
Apr 18, 2024
primary completion
Apr 18, 2028
completion
Apr 18, 2028
last updated
Mar 10, 2026
official title
A Phase I Study of ADCLEC.syn1 CAR T Cells in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol